{"id":78606,"date":"2018-05-12T10:02:57","date_gmt":"2018-05-12T17:02:57","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2018\/05\/cancer-treatment-changes-cancer-cells-into-normal-ones"},"modified":"2018-05-15T13:10:32","modified_gmt":"2018-05-15T20:10:32","slug":"cancer-treatment-changes-cancer-cells-into-normal-ones","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2018\/05\/cancer-treatment-changes-cancer-cells-into-normal-ones","title":{"rendered":"Cancer treatment changes cancer cells into normal ones"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/cancer-treatment-changes-cancer-cells-into-normal-ones2.jpg\"><\/a><\/p>\n<p>BGN Technologies, the technology-transfer company of Ben-Gurion University of the Negev (BGU), announced that a research group led by Prof. Varda Shoshan-Barmatz of the BGU Department of Life Sciences and the National Institute for Biotechnology in the Negev, is developing a new molecule to treat cancer that inhibits cancer cell growth and changes these cells back to normal ones.<\/p>\n<p>\u201cAlthough this is in the early stages, we are excited with results that demonstrate this novel molecule\u2019s potential for <a href=\"https:\/\/medicalxpress.com\/tags\/cancer+treatment\/\" rel=\"tag\" class=\"\">cancer treatment<\/a>,\u201d says Prof. Shoshan-Barmatz. \u201cBasically, we\u2019ve discovered a code for reprograming cancer cells that causes them to lose their oncogenic features.\u201d<\/p>\n<p>The novel treatment is based on siRNA (small interfering ribonucleic acid), which silences expression of the mitochondrial gatekeeper protein, VDAC1. This protein is highly overexpressed in many solid and non-solid tumors and is crucial for supplying the high energy demands of malignant cells.<\/p>\n<p><!-- Link: <a href=\"https:\/\/m.medicalxpress.com\/news\/2018-05-cancer-treatment-cells.html\">https:\/\/m.medicalxpress.com\/news\/2018&#45;05-cancer-treatment-cells.html<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BGN Technologies, the technology-transfer company of Ben-Gurion University of the Negev (BGU), announced that a research group led by Prof. Varda Shoshan-Barmatz of the BGU Department of Life Sciences and the National Institute for Biotechnology in the Negev, is developing a new molecule to treat cancer that inhibits cancer cell growth and changes these cells [\u2026]<\/p>\n","protected":false},"author":476,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-78606","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/78606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/476"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=78606"}],"version-history":[{"count":1,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/78606\/revisions"}],"predecessor-version":[{"id":78759,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/78606\/revisions\/78759"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=78606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=78606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=78606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}